Last Updated:
10:16 am
Friday, June 27, 2025
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses on understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.
asx-ixc
Market Cap
AU$6.69M
Volume
1213
Open
0.09
AU$
High
0.09
AU$
Low
0.09
AU$
Shares On Issue
75M
52 Week Low
0.059
AU$
52 Week High
0.1
AU$
Website
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved